key: cord-0886947-y1ymx792 authors: Oster, Yonatan; Benenson, Shmuel; Nir-Paz, Ran; Buda, Inon; Cohen, Matan J. title: The effect of a third BNT162b2 vaccine on breakthrough infections in healthcare workers: a cohort analysis date: 2022-02-07 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.01.019 sha: 2e8682e5bb0c39871382dd03ce134e5b1a3dcc33 doc_id: 886947 cord_uid: y1ymx792 OBJECTIVES: In August 2021, six months following a mass vaccination of the Israeli population by the two-dose BNT162b2 mRNA vaccine, a surge of COVID-19 infections, mostly by the Delta variant, appeared also among the vaccinated. In response, the Israeli Ministry of Health initiated a booster (third dose) vaccination program. We assessed the protective effect of the third dose among healthcare workers (HCW). METHODS: Infections by SARS-CoV-2 are monitored systematically among HCW at the Hadassah tertiary care medical center in Jerusalem, Israel. In this cohort, we included breakthrough infections, defined as those occurring more than 180 days since the second vaccine dose. The follow-up period lasted 120 days. We compared infection rates between HCW who received the booster dose and those who received only the two-dose regimen. RESULTS: The rate of breakthrough infections among HCW who received only the 2-dose regimen, was 21.4% (85/398). The rate in the boosted group was 0.7% (35/4973; relative risk 30, 95% CI 20-50). Those results were seen in all age groups. CONCLUSIONS: The significantly lower rate of breakthrough infections in boosted HCW indicates substantial protection by a third vaccine dose. Vaccination against SARS-CoV-2, both in the general population and in healthcare workers (HCW), proved to be a major leap in coping with the COVID-19 pandemic (1, 2) . Israel implemented its two-dose vaccination program with the BNT162b2 vaccine at the end of 2020. After several months of extremely low infection rates, a fourth COVID-19 wave appeared, consisting mainly of the Delta variant, which also affected two-dose vaccinated persons. Presuming that waning immunity was the chief cause, at the end of July 2021 the Israeli Ministry of Health initiated a novel booster (third dose) vaccination program. Implementation was initiated with scarce supporting data, and debate on both necessity and age limits ensued (3, 4) . Initially, people over the age of 60 years, immunocompromised, and HCW were vaccinated, followed gradually by the general adult population (5) . We collected data on breakthrough infections, both in booster recipients and in those who chose not to receive the third dose, in order to assess the real-life effectiveness of this vaccine on HCW breakthrough infections. J o u r n a l P r e -p r o o f Jerusalem, Israel. Vaccinated workers are not routinely screened for SARS-CoV-2; they are tested by PCR following significant exposures or symptoms. We compared breakthrough infection rates between HCW who had received a two-dose BNT162b2 regimen at least six months earlier and those who received a third (booster) dose. The study population included all HCW who received two vaccine doses. Of these, (Table) . Booster vaccination rates among male and female HCW were 1744/1835 (95%) and 3229/3536 (91%), respectively (p<0.001). Vaccination rates according to profession were: 96% among physicians, 91% among nurses, and 92% in other sectors. No major side effects or safety issues were described following the booster dose administration, although these data were not collected systematically. Overall, booster recipients had remarkably reduced infection risk in the 120 days following vaccination. The breakthrough infection rate in the two-dose group was 85/398 (21%) and in the booster group 35/4973 (0.7%; relative risk 30, 95%CI 20-50). Similar effectiveness was observed in all age groups (Table) . The most distinctive protection was noted in those older than 45 years, with a 30% absolute risk reduction (p<0.001). Almost all breakthrough infections were mild or asymptomatic; there was only one HCW requiring a short hospitalization in each group. These results clearly show that a booster vaccine dose with BNT162b2 significantly improved protection against SARS-CoV-2, during the Delta variant surge. This effect was seen in all age groups, most conspicuously in those older than 45 years. The rate of booster receipt was higher in male HCW and in physicians versus other HCW. The gender difference might be explained by pregnancy or fertility-related concerns. In all subgroups, however, vaccination rates were higher than 90%. This is an impressive compliance rate considering the paucity of information supporting this strategy. The sudden appearance of breakthrough infections among two-dose vaccinated persons could be explained either by waning immunity or by weaker vaccine protection against new variants (i.e., Delta variant at that time). The Israeli Ministry of Health's decision to recommend a third dose was made in times of uncertainty. These results ultimately support that decision, as do studies showing decreases in antibody titers six months following the second vaccine dose (6) . The protective effect of the booster dose against infection has also been seen in the community setting and in persons older than 60 years (5, 7) . Additionally, the booster vaccine has been shown to prevent severe outcomes (8) . A similar dilemma exists these days regarding a surge of breakthrough infections among boosted individuals, caused primarily by the Omicron variant. A limitation of this study is the lack of routine testing for SARS-CoV-2 of HCW in our hospital, thus some infections were probably missed. However, in our hospital PCR tests for SARS-CoV-2 are easily available for all HCW as previously described (9) and J o u r n a l P r e -p r o o f both groups. Another limitation is the lack of systematic monitoring of adverse events following the booster; no vaccine-related serious adverse events were reported, however, with no HCW hospitalized due to a vaccine-related event. In conclusion, our study demonstrates strong protection from SARS-CoV-2 infection by a booster dose, which in turn reduces unnecessary isolation and quarantine, thus enabling optimal hospital functioning . J o u r n a l P r e -p r o o f <0.001 $ Percent of total participants in the subgroup. * Percent of breakthrough infections per study group and per subgroup (gender; profession; age group). # Log-rank p-value comparing two-dose vs. three-dose groups. Vaccine Effectiveness among Health Care Workers Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data Considerations in boosting COVID-19 vaccine immune responses Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Waning Immunity after the BNT162b2 Vaccine in Israel Effectiveness of a third dose of BNT162b2 mRNA vaccine Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study Proactive screening approach for SARS-CoV-2 among healthcare workers The authors would like to thank the Hadassah workers operating the vaccine project Author contributions: